[Form 4] L3HARRIS TECHNOLOGIES, INC. /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Christopher E. Kubasik, Chair and CEO of L3Harris Technologies (LHX), reported option exercise and a contemporaneous sale on 09/12/2025 under a Rule 10b5-1 plan. He exercised 83,000 non-qualified stock options with an exercise price of $162.30 per share that were originally granted 06/29/2019 and expire 02/20/2028, resulting in acquisition of 83,000 shares. The reporting person then sold 83,000 shares at a weighted-average price in the reported range of $278.30 to $281.62 (disclosed average shown as $279.90). Following these transactions, beneficial ownership is reported as 145,577.82 shares directly and indirectly, which includes 30,000 shares held indirectly through a grantor retained annuity trust.

Positive

• Transaction executed pursuant to a Rule 10b5-1 plan, indicating pre-arranged compliance with insider trading rules
• Options exercised were vested (grant date 06/29/2019 and exercisable), demonstrating established compensation realization

Negative

• Sale of 83,000 shares reduced direct beneficial ownership from 228,577.82 to 145,577.82, a sizable change in reported holdings
• Filing lacks details about the 10b5-1 plan start date and allocation of proceeds, limiting context for investors

Insights

Financial Analyst

TL;DR: CEO exercised vested options and sold the resulting shares under a 10b5-1 plan; routine execution with limited disclosure of intent.

The filing documents a typical executive liquidity event: exercise of 83,000 non-qualified options granted in 2019 at $162.30 and immediate sale of the 83,000 resulting shares at prices within $278.30–$281.62. The sale was indicated as executed pursuant to a written plan intended to meet Rule 10b5-1 affirmative defense conditions. The transactions materially changed reported beneficial ownership figures but do not include commentary on use of proceeds or any change in ongoing compensation arrangements. For investors, the filing confirms option vesting and execution dates, the exercise price, and the realized sale price range—all explicitly stated.

Corporate Governance Expert

TL;DR: Disclosure shows compliance with trading-plan protocols; transaction is a standard insider exercise-and-sell event.

The report identifies the reporting person as both Chair and CEO and marks the transaction as pursuant to a 10b5-1 plan. This alignment with an established trading plan is relevant for governance and insider-trading oversight because it signals pre-planned execution rather than opportunistic trading. The filing also includes the attorney-in-fact signature, satisfying procedural formality. The report does not, however, state the start date of the 10b5-1 plan or any aggregated holdings schedule beyond the post-transaction balances, so oversight assessments are limited to the presented facts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUBASIK CHRISTOPHER E

(Last) (First) (Middle)

C/O L3HARRIS TECHNOLOGIES, INC.

1025 W. NASA BOULEVARD

(Street)

MELBOURNE FL 32919

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
L3HARRIS TECHNOLOGIES, INC. /DE/ [ LHX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chair and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, Par Value $1.00	09/12/2025		M		83,000	A	$0	228,577.82	D
Common Stock, Par Value $1.00	09/12/2025		S		83,000	D	$279.9	145,577.82(1)	D
Common Stock, Par Value $1.00								30,000	I	By grantor retained annuity trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$162.3	09/12/2025		M			83,000	06/29/2019	02/20/2028	Common Stock Par Value $1.00	83,000	$0	14,171	D

Explanation of Responses:

1. Reflects the weighted average sale price (prices actually received ranged from $278.30 to $281.62). The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	By: /s/ John C. Scarborough, Jr., Attorney-in-Fact For: Christopher E. Kubasik	09/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did LHX insider Christopher Kubasik report on 09/12/2025?

He exercised 83,000 non-qualified stock options at $162.30 and sold 83,000 shares at an average price in the disclosed range of $278.30–$281.62.

Were these trades part of a pre-arranged plan for LHX (ticker: LHX)?

Yes. The form is marked to indicate the sale was made pursuant to a contract, instruction or written plan intended to satisfy Rule 10b5-1 conditions.

How many LHX shares does Kubasik beneficially own after the transactions?

The report lists 145,577.82 shares beneficially owned following the reported transactions, including 30,000 indirectly held via a grantor retained annuity trust.

What was the exercise price and expiration for the options exercised?

The non-qualified stock options had an exercise price of $162.30, grant date 06/29/2019, and expiration date 02/20/2028.

Does the filing disclose the exact sale price per share?

The filing discloses a weighted average sale price shown as $279.90 and a price range of $278.30 to $281.62; the filer offered to provide the number of shares sold at each price upon request.